How do we optimally use cetuximab in first-line treatment for metastatic colorectal cancer?

By Lindsay Colin R   Roxburgh Patricia   Graham Janet  

Future Oncology, Vol. 9, Iss. 6, 2013-06 ,pp. : 825-829

Future Medicine

Access to resources Recommend Favorite

Secondary treatment and predictive factors for second-line chemotherapy after first-line oxaliplatin-based therapy in metastatic colorectal cancer

By Sørbye Halfdan   Berglund Åke   Tveit Kjell Magne   Øgreid Dagfinn   Wanderås Eva Hoff   Wentzel-Larsen Tore   Dahl Olav   Glimelius Bengt  

Acta Oncologica, Vol. 46, Iss. 7, 2007-01 ,pp. : 982-988

Informa Healthcare

Access to resources Recommend Favorite

Anti-VEGF and Anti-EGFR Monoclonal Antibodies in the First-line Therapy for Metastatic Colorectal Cancer - A Meta-Analysis

By  

Current Cancer Therapy Reviews, Vol. 7, Iss. 4, 2011-11 ,pp. : 282-289

Bentham Science Publishers

Access to resources Recommend Favorite

Early tumor shrinkage in patients with metastatic colorectal cancer receiving first-line treatment with cetuximab combined with either CAPIRI or CAPOX: An analysis of the German AIO KRK 0104 trial

By Modest Dominik P.   Laubender Ruediger P.   Stintzing Sebastian   Giessen Clemens   Schulz Christoph   Haas Michael   Mansmann Ulrich   Heinemann Volker  

Acta Oncologica, Vol. 52, Iss. 5, 2013-06 ,pp. : 956-962

Informa Healthcare

Access to resources Recommend Favorite

Vinorelbine, Epirubicin and Fluorouracil as First-Line Therapy in Metastatic Breast Cancer

By Elomaa Inkeri   Joensuu Heikki   Blomqvist Carl  

Acta Oncologica, Vol. 42, Iss. 4, 2003-01 ,pp. : 309-314

Informa Healthcare

Access to resources Recommend Favorite